Nuvation Bio Inc.
NUVBNYSE
$5.80
↑ +2.8%Jul 17 close · end-of-day
Price
1Y↑ +160.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.2M
Enterprise Value
-$478.4M
P/E
—
P/S
0.0
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$143.0M
Net Income (TTM)
-$146.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-105.0%
Net Margin
-102.1%
ROE
-45.7%
ROIC
—
Debt / Equity
0.2
Net Cash
$480.6M
Return 1Y
+158.9%
Company profile
Nuvation Bio Inc. focuses on the development of therapeutic candidates for oncology. Lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. Company was formerly known as RePharmation Inc.
- CEO
- David T. Hung
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- California
- Website
- nuvationbio.com
Management & directors
- Sauvage PhilippeChief Financial Officer
- Markel StacyCHIEF PEOPLE OFFICER
- Wentworth KerryCHIEF REGULATORY OFFICER
- Liu DongfangCHIEF MEDICAL OFFICER
- Makunje MosesSEE REMARKS
- Hattersley GaryCHIEF SCIENTIFIC OFFICER
- Hanley David C.CHIEF TECHNICAL OPERATIONS
- Hung DavidPRESIDENT AND CEO
- Sjogren ColleenChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
NUVB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$83.2M↑ +2598.7%
Diluted EPS$0.01↓ -106.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $7.9M | $62.9M |
| Gross profit | — | — | — | $0.00 | $795,000.00 | — |
| Operating income | -$43.6M | -$93.3M | -$119.7M | -$99.8M | -$592.6M | -$213.1M |
| Net income | -$41.7M | -$86.8M | -$104.2M | -$75.8M | -$567.9M | -$204.6M |
| Diluted EPS | — | -$0.44 | -$0.48 | -$0.35 | -$2.11 | -$0.60 |
| Operating cash flow | -$36.5M | -$68.2M | -$96.1M | -$68.0M | -$130.4M | -$173.4M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | 10.1% | — |
| Operating margin | — | — | — | — | -7527.3% | -338.7% |
| Net margin | — | — | — | — | -7213.8% | -325.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $727,000.00 | $5.7M | $3.1M | $4.8M | $13.1M | $41.9M | $83.2M |
| Gross profit | $88,000.00 | -$788,000.00 | $1.5M | $990,000.00 | $2.3M | $9.8M | — | — |
| Operating income | -$470.4M | -$48.1M | -$53.9M | -$59.0M | -$63.6M | -$56.4M | -$34.0M | $3.9M |
| Net income | -$462.5M | -$41.2M | -$49.4M | -$53.2M | -$59.0M | -$55.8M | -$36.6M | $5.4M |
| Diluted EPS | -$1.89 | -$0.15 | $0.00 | -$0.16 | -$0.17 | -$0.16 | -$0.11 | $0.01 |
| Operating cash flow | -$37.3M | -$31.1M | -$46.3M | -$42.6M | -$48.2M | -$52.9M | -$29.7M | $5.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 6.1% | -108.4% | 26.2% | 32.1% | 46.7% | 74.5% | — | — |
| Operating margin | -32779.4% | -6616.4% | -944.5% | -1913.2% | -1315.7% | -430.1% | -81.3% | 4.7% |
| Net margin | -32229.4% | -5668.5% | -865.8% | -1726.2% | -1220.9% | -425.2% | -87.4% | 6.5% |
Company news
Jul 20, 2026
- 4h agoSector Update: Healthcare Stocks Fall Late Afternoonfinance.yahoo.com
- 6h agoNUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drugstocktwits.com
- 11h agoNuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Gliomafinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Sauvage Philippe· Chief Financial Officer | Option exercise | 39,999 | $2.17 | $86,797.83 | filing |
| 2026-07-15 | Sauvage Philippe· Chief Financial Officer | Option exercise | 1 | $1.97 | $1.97 | filing |
| 2026-06-23 | Markel Stacy· CHIEF PEOPLE OFFICER | Sale | 125,000 | $6.03 | $753,187.50 | filing |
| 2026-06-23 | Wentworth Kerry· CHIEF REGULATORY OFFICER | Sale | 63,000 | $6.02 | $379,190.70 | filing |
| 2026-06-23 | Sauvage Philippe· Chief Financial Officer | Sale | 47,668 | $6.01 | $286,370.28 | filing |
| 2026-06-23 | Wentworth Kerry· CHIEF REGULATORY OFFICER | Option exercise | 63,000 | $2.93 | $184,590.00 | filing |
| 2026-06-23 | Markel Stacy· CHIEF PEOPLE OFFICER | Option exercise | 90,380 | $1.87 | $169,010.60 | filing |
| 2026-06-23 | Sauvage Philippe· Chief Financial Officer | Option exercise | 47,668 | $2.17 | $103,439.56 | filing |
| 2026-06-23 | Markel Stacy· CHIEF PEOPLE OFFICER | Option exercise | 34,620 | $1.74 | $60,238.80 | filing |
| 2026-06-09 | Mashal Robert | Buy | 25,000 | $4.73 | $118,250.00 | filing |
| 2026-04-17 | Liu Dongfang· CHIEF MEDICAL OFFICER | Sale | 50,000 | $5.02 | $251,000.00 | filing |
| 2026-04-17 | Wentworth Kerry· CHIEF REGULATORY OFFICER | Sale | 36,750 | $5.01 | $184,279.20 | filing |
| 2026-04-17 | Wentworth Kerry· CHIEF REGULATORY OFFICER | Option exercise | 36,750 | $2.93 | $107,677.50 | filing |
| 2026-04-17 | Liu Dongfang· CHIEF MEDICAL OFFICER | Option exercise | 50,000 | $1.94 | $97,000.00 | filing |
| 2026-04-06 | Wentworth Kerry· CHIEF REGULATORY OFFICER | Sale | 200,000 | $4.52 | $903,560.00 | filing |
| 2026-04-06 | Wentworth Kerry· CHIEF REGULATORY OFFICER | Option exercise | 100,000 | $1.94 | $194,000.00 | filing |
| 2026-04-06 | Wentworth Kerry· CHIEF REGULATORY OFFICER | Option exercise | 100,000 | $1.87 | $187,000.00 | filing |
| 2026-02-27 | Makunje Moses· SEE REMARKS | Award | 50,761 | $0.00 | $0.00 | filing |
| 2025-12-01 | Liu Dongfang· CHIEF MEDICAL OFFICER | Sale | 150,000 | $7.82 | $1.2M | filing |
| 2025-12-01 | Liu Dongfang· CHIEF MEDICAL OFFICER | Option exercise | 150,000 | $2.93 | $439,500.00 | filing |
| 2025-11-26 | Liu Dongfang· CHIEF MEDICAL OFFICER | Sale | 10,000 | $8.00 | $80,000.00 | filing |
| 2025-11-26 | Liu Dongfang· CHIEF MEDICAL OFFICER | Option exercise | 10,000 | $3.61 | $36,100.00 | filing |
| 2025-11-25 | Liu Dongfang· CHIEF MEDICAL OFFICER | Sale | 10,000 | $7.50 | $75,000.00 | filing |
| 2025-11-25 | Liu Dongfang· CHIEF MEDICAL OFFICER | Option exercise | 10,000 | $3.61 | $36,100.00 | filing |
| 2025-11-20 | Hattersley Gary· CHIEF SCIENTIFIC OFFICER | Sale | 300,000 | $7.23 | $2.2M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.